Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation

  • Martinez-Campanario, M. C.
  • Cortés, Marlies
  • Moreno-Lanceta, Alazne
  • Han, Lu
  • Ninfali, Chiara
  • Domínguez, Verónica
  • Andrés-Manzano, María J.
  • Farràs, Marta
  • Esteve-Codina, Anna
  • Enrich, Carlos
  • Díaz-Crespo, Francisco J.
  • Pintado, Belén
  • Escolà-Gil, Joan Carles
  • García de Frutos, Pablo
  • Andrés, Vicente
  • Melgar-Lesmes, Pedro
  • Postigo, Antonio
Accumulation of lipid-laden macrophages within the arterial neointima is a critical step in atherosclerotic plaque formation. Here, we show that reduced levels of the cellular plasticity factor ZEB1 in macrophages increase atherosclerotic plaque formation and the chance of cardiovascular events. Compared to control counterparts (Zeb1 /Apoe ), male mice with Zeb1 ablation in their myeloid cells (Zeb1 /Apoe ) have larger atherosclerotic plaques and higher lipid accumulation in their macrophages due to delayed lipid traffic and deficient cholesterol efflux. Zeb1 /Apoe mice display more pronounced systemic metabolic alterations than Zeb1 /Apoe mice, with higher serum levels of low-density lipoproteins and inflammatory cytokines and larger ectopic fat deposits. Higher lipid accumulation in Zeb1 macrophages is reverted by the exogenous expression of Zeb1 through macrophage-targeted nanoparticles. In vivo administration of these nanoparticles reduces atherosclerotic plaque formation in Zeb1 /Apoe mice. Finally, low ZEB1 expression in human endarterectomies is associated with plaque rupture and cardiovascular events. These results set ZEB1 in macrophages as a potential target in the treatment of atherosclerosis., IDIBAPS is partly funded by the Generalitat of Catalonia’s CERCA Programme. The studywas conducted at the IDIBAPS’ Centre de Recerca Biomèdica Cellex building,which was partly funded by the Cellex Foundation. The different parts of this study were independently funded by grants to A.P. from the Catalan Agency forManagement of University and Research Grants (AGAUR) (2021-SGR- 01328), and Spanish State Research Agency (AEI) (PID2020-116338RBI00) of the Ministry of Science and Innovation (MICINN), as part of the 2021–2023 Plan for Scientific and Technical Research and Innovation (PEICTI), which is co-financed by the European Regional Development Fund (ERDF) of the European Union Commission. A.M.-L. is a recipient of a PhD scholarship from MICINN (FPI Program) (PRE2019-088097). A.E.- C’s salary is covered by grant PT17/0009/0019 from Carlos III Spanish Health Institute (ISCIII, co-funded by the ERDF) to CNAG. CNIC is supported by MCINN, ISCIII, the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/ 10.13039/501100011033). P.M.-L. salary is supported by a fellowship from AEI’s Ramon y Cajal Program (RYC2018-0Z23971-I). L.H. is supported by a PhD scholarship from the China Scholarship Council (202208110041)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans

  • Córdoba-Jover, Bernat
  • Ribera, Jordi
  • Portolés, Irene
  • Lecue, Elena
  • Rodriguez-Vita, Juan
  • Pérez-Sisqués, Leticia
  • Mannara, Francesco
  • Solsona-Vilarrasa, Estel
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Casals, Gregori
  • Rodríguez-Revenga, Laia
  • Álvarez-Mora, María Isabel
  • Arteche-López, Ana
  • Díaz de Bustamante, Aranzazu
  • Calvo, Rosa
  • Pujol, Anna
  • Azkargorta, Mikel
  • Elortza, Felix
  • Malagelada, Cristina
  • Pinyol, Roser
  • Huguet-Pradell, Júlia
  • Melgar-Lesmes, Pedro
  • Jiménez, Wladimiro
  • Morales-Ruiz, Manuel
Transcription co-activator factor 20 (TCF20) is a regulator of transcription factors involved in extracellular matrix remodelling. In addition, TCF20 genomic variants in humans have been associated with impaired intellectual disability. Therefore, we hypothesized that TCF20 has several functions beyond those described in neurogenesis, including the regulation of fibrogenesis., We acknowledge the support from grants PDI2019-105502RB-100 and PID2022-138243OB-I00 to MM-R, PID2019-111669RB, BES-2017-080823 to IP "ESF Investing in your future", and RTI2018-094734-B-C21 to WJ and PM-L, from MCIN/AEI/10.13039/501100011033. RedFibro (RED2022-134485-T) of the 2022 caLL for aid to «RESEARCH NETWORKS», within the framework of the Programa Estatal del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021–2023. Consolidated Research Group of the Generalitat de Catalunya AGAUR (2021 SGR 00881 to MM-R) and PM-L financed ESF Investing in your future, support from AGAUR of the Generalitat de Catalunya. Fundación Mutua Madrileña AP171442019, European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, and the Project 201 916/31 Contribution of mitochondrialoxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3. PM-L was additionally supported by a fellowship from the Ramon y Cajal Program (RYC2018-0Z23971-I) and a grant (PID2021-123426OB-I00) from the Spanish Ministerio de Ciencia, Innovación y Universidades. CIBERehd is financed by the Instituto de Salud Carlos III., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats

  • Perramón Corominas, Meritxell
  • Navalón López, María
  • Fernández Varo, Guillermo
  • Moreno Lanceta, Alazne
  • García Jiménez, Rocío
  • Faneca Farrés, Joana
  • López-Moya, Mario
  • Fornaguera, Cristina
  • García-Villoria, Judith
  • Morales-Ruiz, Manuel
  • Melgar Lesmes, Pedro
  • Borrós, Salvador
  • Jiménez, Wladimiro
Nitric oxide (NO) is a small vasodilator playing a key role in the pathogenesis of portal hypertension. Here, we assessed the potential therapeutic effect of a NO donor targeted to the liver by poly(beta-amino ester) nanoparticles (pBAE NPs) in experimental cirrhosis. Retinol-functionalized NO donor pBAE NPs (Ret pBAE NPs) were synthetized with the aim of actively targeting the liver. Administration of Ret pBAE NPs resulted in uptake and transfection by the liver and spleen. NPs were not found in other organs or the systemic circulation. Treatment with NO donor Ret pBAE NPs (30 mg/ kg body weight) significantly decreased aspartate aminotransferase, lactate dehydrogenase and portal pressure (9.75 ± 0.64 mmHg) compared to control NPs (13.4 ± 0.53 mmHg) in cirrhotic rats. There were no effects on mean arterial pressure and cardiac output. Liver-targeted NO donor NPs reduced collagen fibers and steatosis, activation of hepatic stellate cells and mRNA expression of profibrogenic and proinflammatory genes. Finally, Ret pBAE NPs displayed efficient transfection in human liver slices. Overall, liver-specific NO donor NPs effectively target the liver and mitigated inflammation and portal hypertension in cirrhotic rats. The use of Ret pBAE may prove to be an effective therapeutic strategy to treat advanced liver disease., info:eu-repo/semantics/publishedVersion